Amicus director exits holdings in BioMarin buyout
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics director Margaret G. McGlynn reported disposing of her equity positions in connection with the consummation of the acquisition of Amicus by BioMarin Pharmaceutical Inc. She surrendered 94,631 shares of Common Stock, including 31,000 shares and 63,631 restricted stock units that vested in full at closing.
Multiple fully vested stock options were also cancelled and converted into cash. For each option, she became entitled to a cash payment equal to $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. Following these transactions, her reported direct holdings of Common Stock and options are shown as zero.
Insider Trade Summary
Disposition: 398,261 shares
Disposition
10 txns
Insider
MCGLYNN MARGARET G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 20,000 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 16,236 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 19,473 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 18,574 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 36,111 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 45,423 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 30,474 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 42,467 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 74,872 | $0.00 | $0.00 |
| Disposition | Common Stock | 94,631 | $14.50 | $1.37M |
Holdings After Transaction:
Stock Options (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger).
- F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- F3. Each Option was fully vested.
- F4. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares disposed: 94,631 shares
Merger cash price: $14.50 per share
Restricted stock units vested: 63,631 RSUs
+4 more
7 metrics
Common shares disposed
94,631 shares
Disposition of Common Stock in connection with BioMarin acquisition
Merger cash price
$14.50 per share
Cash consideration used to value option cancellation payments
Restricted stock units vested
63,631 RSUs
RSUs that vested in full upon consummation of the merger
Common shares component
31,000 shares
Portion of the 94,631 Common Stock shares referenced in footnote
Option strike price example
$5.96 per share
Exercise price for one cancelled stock option grant
Option strike price example
$12.62 per share
Exercise price for another cancelled stock option grant
Post-transaction holdings
0 shares/options
Total shares and option shares shown following reported dispositions
Key Terms
restricted stock units, stock option, Merger, cash payment, +2 more
6 terms
restricted stock units financial
"which included 31,000 shares of Common Stock and 63,631 restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Merger financial
"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
cash payment financial
"was cancelled and converted into the right to receive a cash payment equal to"
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"Each Option was fully vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Margaret G. McGlynn report at Amicus Therapeutics (FOLD)?
Margaret G. McGlynn reported disposing of her Amicus Therapeutics equity in connection with the company’s acquisition by BioMarin. She surrendered common shares, vested restricted stock units, and multiple fully vested stock options, all treated as dispositions to the issuer tied to the merger closing.
What happened to Margaret G. McGlynn’s Amicus Therapeutics (FOLD) stock options in the BioMarin merger?
Each reported stock option held by Margaret G. McGlynn was cancelled at the merger closing. In exchange, she became entitled to a cash payment equal to $14.50 per share minus the option’s exercise price, multiplied by the number of shares underlying each option grant.
Does Margaret G. McGlynn report any remaining Amicus Therapeutics (FOLD) holdings after the merger transactions?
The Form 4 shows zero shares of Common Stock and zero corresponding option shares following the reported transactions. This indicates her disclosed direct holdings of Amicus common stock and the listed stock options were fully disposed of in connection with completion of the BioMarin acquisition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
